GLPG Earnings

GLPG reported its earnings on 2026-02-23, showcasing a revenue of 1.05B against an estimate of 83.81M, resulting in a 1151.64% surprise. The EPS was 13.82, surpassing the expected 1 by 1281.8%. The stock experienced a 0.3% price change on the earnings day and a -0.83% change over the next five days, reflecting market reactions to the results.

Following GLPG's earnings announcement on 2026-02-23, the stock price moved by 0.3% on the day of the release. Over the subsequent five days, it saw a -0.83% change. Historically, GLPG's stock price tends to shift by an average of -3.08% in the 10 days leading up to earnings and 0.3% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate GLPG's annual revenue to reach 71.08M, while the EPS is projected at -1.21. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GLPG's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GLPG's stock price typically moves by -3.08% in the 10 days before its earnings and 0.3% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -1.21 and revenue of 71.08M.

The earnings call reveals several negative factors: significant financial impacts from the cell therapy wind-down, strategic reorganization costs, and currency exchange risks. Although there is a strong cash position and improved operating profit, the dependency on Gilead and lack of clear guidance on cost management raise concerns. The Q&A section highlights management's avoidance of specifics on cost reduction and breakeven timelines, adding uncertainty. These factors, combined with the strategic reorganization costs and potential financial challenges, suggest a negative stock price movement in the next two weeks.